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ABSTRACT
Testing for Transferred Immunity of a Universal Influenza Vaccine in Pigs
Rachel Sestak
Director: Victor Huber, Ph.D.
Influenza causes high numbers of illnesses and deaths annually (CDC, 2020).
Influenza vaccines prevent these complications by reducing the risk of flu illness between
40-60% (CDC, 2021). However, no vaccination exists for infants under six months old so
other methods, such as passive immunity, must be explored. To determine how infants
can be protected, we tested the passive transfer of a universal influenza vaccine using a
pig model and researched the mechanism of transfer. Four pregnant pigs were vaccinated
one time with PBS and one time with HA-129 vaccine and four were vaccinated twice
with the HA-129 vaccine. After farrowing, piglets were challenged with influenza virus
and nasal swabs were taken and analyzed to determine whether piglets were infected. We
tested the hypothesis that if vaccinated mother pigs transfer high levels of antibodies to
the newborn, then antibodies will protect influenza-challenged offspring from the virus.
Our results found higher mean viral titer values for the PBS vaccinated group indicating
higher levels of infection. Despite error within research protocols, such as the lack of a
true PBS group, we can predict that influenza vaccination of mothers may lead to the
protection of piglets. Our research forms a basis for vaccination of pregnant mothers to
protect the immunocompromised mother and vulnerable newborn.
Keywords: Influenza, Maternal, Transfer, Pigs, Immunity, Vaccine, Universal
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CHAPTER ONE
Introduction
The History of Influenza
The words epidemic and pandemic have been a central theme of discussion
throughout the past two years. An epidemic is an increase in the prevalence of disease
above the expected number in the population, while a pandemic is an epidemic that
affects many people and spreads over several continents (CDC, 2012). These
classifications are not new, as they have been applied to the influenza virus for at least
three hundred years (Potter, 2001). Epidemics and pandemics occur due to an increase in
virulence or ability to cause disease, a lack of natural immune responses to the antigen,
and increased transmissibility (CDC, 2012). Specific genetic mutations affecting the viral
life cycle are called virulence determinants, which contribute to increased severity and
transmissibility in highly pathogenic phenotypes of the influenza virus (Tscherne, 2011).
These mutations include factors increasing evasion of innate and adaptive immune
response; changing genome replication, transcription, and translation; and altering virus
binding, entry, assembly, and release (Tscherne, 2011). A major example of a virulence
determinant is hemagglutinin changes that rapidly increase viral transmission (Tscherne,
2011). Transmission of the influenza virus is an ongoing struggle that decreases global
health annually due to high mutation rates and increased antigenic variation, which
decreases the natural ability of the immune system to respond to the virus. These
characteristics create difficulties in establishing a protective vaccine (Abbas, 2020). A
lack of herd immunity, yearly vaccination requirements, and insufficient natural
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responses allow for the high transmissibility of influenza between hosts, resulting in the
high infection rates seen each year.
The issues of antigenic variation and a lack of herd immunity cause the world to
be impacted by influenza epidemics every year and pandemics every ten to fifty years,
typically during the winter months (Potter, 2001). Influenza epidemics have been
recorded throughout history with the first possible Greek epidemic occurring in 412 BCE
(Ghendon, 1994 & Potter, 2001). The first report of an epidemic with clear symptoms
aligning with influenza occurred in 1173 followed by several reports of influenza
outbreaks in the 14th and 15th centuries which are considered indisputable influenza
epidemics (Ghendon, 1994). These early epidemics were followed by records in America
and Europe during the 17th century, accounts in the 18th and 19th centuries, and current
infections continuing today (Potter, 2001). Epidemics are generally limited to specific
geographic areas and cause fewer worldwide death rates; meanwhile, pandemics cause
high death rates and spread to much of the world’s population. Pandemics caused by the
influenza virus have negatively impacted population health throughout history. This
impact can be seen by recognizing the most notable pandemics. During the outbreak of
1510 in Africa and Europe, people experienced cough, fever, and constriction (Morens,
2010). This was the first recognition of pandemic influenza with a high attack rate and
few deaths, but the effects of influenza were much more devastating during the highly
transmissible and deadly 1580 pandemic beginning in Asia and spreading globally with a
95% infection rate in Europe and 8,000 deaths in Rome (Ghendon, 1994 & Potter, 2001).
Subsequent pandemics with high global transmission rates were seen during the 1729
pandemic, which imposed high death rates globally with increased severity in later waves
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of infection; the 1781 pandemic with high morbidity and mortality rates in young adults;
and the 1830 pandemic characterized by low death rates (Potter, 2001). During 1918-19,
a pandemic that was first classified as bacterial emerged; however, in1933, it was
characterized as the first influenza virus originating from swine and the variant was
classified as the HswN1 subtype (Barberis, 2016; Ghendon, 1994). The 1918 pandemic,
also known as the Spanish Flu, is characterized as one of the most destructive pandemics
causing forty to fifty million deaths with infection of half of the world’s population
(Ghendon, 1994; Potter, 2001). The severity caused public events to cease, schools and
churches to close, and masking to be implemented (Ghendon, 1994). The 1957-1958
pandemic of the H2N2 virus emerged from avian origin and infected 40% to 50% of the
world’s population and killed about one million (Tscherne, 2011). Another avian virus
(H3N2) was prominent in the 1968 pandemic, killing one million people worldwide.
Lastly, the 2009 pandemic of H1N1 originated in swine and caused 60.8 million cases,
274,304 hospitalizations, and 12,469 deaths in the United States and 0.001% to 0.007%
of the world's population died due to infection (CDC, 2019; Potter, 2001). This pandemic
increased the urgency to implement effective pandemic planning, including substantial
efforts to develop universal vaccines to decrease pandemic death rates (Morens, 2010).
Prevalence and Importance
The influenza virus is a leading cause of death and severe disease annually
(Smith, 2018). Although vaccines and antiviral therapies have been developed, the
evolutionary evasion of the immune response continues to cause pandemics (Smith,
2018). The World Health Organization found three to five million cases of severe illness
occur and up to 650,000 people die annually due to respiratory impacts of influenza
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(WHO, 2018; Paget, 2019). Of the 650,000 deaths, 99,000 - 200,000 deaths are
associated with direct lower respiratory infections due to influenza and 292,000 - 518,000
deaths are influenza-associated; these associations include secondary bacterial infections
or poor outcomes of pre-existing disease (Paget, 2019). Annually, the virus accounts for
about two percent of all respiratory deaths globally (Paget, 2019).
The number of respiratory deaths annually varies based on the global region
(Paget, 2019). North and South America experience the highest rates of death due to
influenza with 6.2 deaths per 100,000 people (Paget, 2019). South-East Asia experiences
5.8 deaths, Africa experiences 5.6 deaths, Europe experiences 5.3 deaths, and the Eastern
Mediterranean experiences 4.5 deaths per 100,000 people (Paget, 2019). These
differences are due to variable access to healthcare, regional economic profit, varying
developmental stages of areas, and different levels of crowding. Within global
boundaries, countries experience vast deviations from the average death rates (Cozza,
2021). This can be seen as Mexico and Canada experience death rates of 3.6 to 5.2 deaths
per 100,000 people while Chile, Argentina, Bolivia, and Peru experience death rates of
5.3 to 16.5 per 100,000 people compared to the mean rate of 6.2 deaths per 100,000 in the
Americas (Cozza, 2021). Regional differences within a country also affect influenza
outcomes. This can be seen in India as of those hospitalized due to severe respiratory
infection 36% died in Jodhpur Rajasthan, 7% died in Kerala, 25 % died in Saurashtra,
and 7 % died in Andhra Pradesh (Fischer, 2014). Based on this evidence, geographic
location contributes to variances in influenza morbidities and mortalities.
High mortality and morbidity rates from influenza have not only negatively
impacted the globe, but the illness has had devastating impacts on the United States
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(Smith, 2018). From 2010 to 2020, influenza caused between nine million and forty-one
million illnesses, 140,000-710,000 hospitalizations, and 12,000-52,000 deaths each year
(CDC, 2020). The high transmission, morbidity, and mortality rates due to influenza on
the local, national, and international levels, despite having access to current vaccines,
portray the importance of continuing research to increase the effectiveness of these
protective measures.
The high rates of death and illness create immense stress on healthcare
infrastructure which can overwhelm public health and healthcare delivery systems. The
systems experience stress due to a lack of treatments, equipment, healthcare resources,
healthcare facilities, and personnel (Levin, 2007). Disasters from illness are especially
devastating because every community is impacted, so there is a lack of personnel and
spare medical equipment that can be mobilized for assistance (Levin, 2007). For
example, New York city predicted that if a pandemic were to occur in 2007, 67% of
intensive care unit beds would be filled in the first wave (Levin, 2007). The large number
of infected people in one area increases pandemic severity because it serves as a tool of
transmission, causing an increase in spread to healthcare professionals and visitors
(Levin, 2007). Influenza also places a large financial burden on the healthcare system and
government. This burden includes $3.2 billion in direct medical costs and $8.0 billion in
indirect costs (Putri, 2018). A combination of death tolls, severe illnesses, transmission to
vulnerable groups, and economic burden establishes influenza as an important issue to be
researched and mitigated.
The extreme outcome of influenza infection is death, but influenza also causes
mild to severe symptoms (WHO, 2018). These symptoms include fever, fatigue, dry
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cough, headache and migraines, joint pain, muscle pain, body aches, vomiting, diarrhea,
severe malaise, runny or stuffy nose, and sore throat that last about two weeks for mild
cases (WHO, 2018; CDC, 2021). Moderate complications include ear and sinus
infections (CDC, 2021). Cases that persist or have more severe symptoms may require
hospitalization. Hospitalization is often due to secondary respiratory diseases, such as
pneumonia (CDC, 2021). Other severe complications caused by influenza are
myocarditis, encephalitis, myositis, sepsis, rhabdomyolysis, extreme inflammatory
response, and organ failure (CDC, 2021).
Symptoms and respiratory diseases cause death and severe illness, but certain
populations are affected disproportionately. Those experiencing chronic disease,
weakened immune systems, pregnancy, young age, and old age are more likely to
develop severe disease or complications due to influenza (WHO, 2018). Influenza is
likely to exacerbate symptoms for those with previous medical conditions or chronic
disease, resulting in poorer health outcomes (CDC, 2021; WHO, 2018). Another
vulnerable population includes those that are pregnant (WHO, 2018). During the 1918
pandemic, mortalities of pregnant women were 5.3 to 5.7 per thousand people compared
to 4.9 per thousand in the entire women’s population (Reid, 2005). Further, pregnant
women were two times more likely to develop pneumonic complications, and with these
complications, pregnant women were two times more likely to die than non-pregnant
women (Reid, 2005). The fetus was also affected during 1918-19 as the miscarriages
linked to influenza rose to a height of 1.6 per thousand (Reid, 2005). In the United States,
fetal loss occurred in 26% of uncomplicated influenza cases and 52% of severe cases
among pregnant women (Reid, 2005). Influenza continues to pose a threat after birth. In
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1918-19 at Derbyshire, 3.67% of influenza deaths were infants (Reid, 2005). This
remains a current issue as there were 144 pediatric deaths from 2018 to 2019 and 199
pediatric deaths from 2019 to 2020 due to influenza in the US (CDC, 2021). Those 65
and older are also disproportionately affected, accounting for 67% of global influenzaassociated deaths (Paget, 2019; WHO, 2018). This is an issue as crowded conditions in
nursing homes create an environment of high transmissibility (CDC, 2018).
Immunocompromised individuals also have a greater risk associated with influenza due
to a weakened immune response (WHO, 2018). Each of these vulnerable populations
experience higher mortality rates due to influenza than the general population (WHO,
2018).
Mortalities and poor health outcomes due to infection by pathogens are also
higher in communities experiencing poverty or social marginalization (WHO, 2021).
Although this disparity is recognized, minimal efforts have been allocated to combat the
issue (Quinn, 2014). As a result, low-income households experience greater
hospitalizations, infections, and deaths from influenza (Quinn, 2014). For example, in
2009, in the UK, those with the lowest incomes had an influenza mortality rate three
times higher than middle to high income families (Quinn, 2014). Social factors, such as
race, also correlate with poor health outcomes and higher mortalities in a population.
Rates of hospitalizations are generally higher for minority groups with admission rates
per 100,000 being 68.8 for African Americans, 48.7 for American Indians and Alaska
Natives, 44.5 for Hispanics or Latinos, and 38.1 for Whites (CDC, 2021). Similar trends
based on ethnicity are revealed with higher mortalities and intensive care unit admissions
for minority groups (CDC, 2021). The wealth of a country also impacts the citizens of
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that country's health outcomes. A flu pandemic is very costly, as the World Health
Organization predicts the United States would spend $60 billion each year of a pandemic
and $4.5 billion is spent each year to prepare for a pandemic (WHO, 2021). Poor
countries lack the finances to prepare for and combat a pandemic (WHO, 2021). As a
result, the least developed countries and low-income social groups are impacted the most
by poor health outcomes.
Transmission, Infection, and Immune Reactions
Influenza, a zoonotic virus, poses a high threat to both animal and human
populations (Moreira, 2021). Zoonotic viruses jump from animals to humans; during this
jump, the virulence of the pathogen usually increases (Moreira, 2021). High virulence
contributes to the rapid transmission within the human population. Occasionally, fomites
are responsible for transmission, as the flu virus may be present on a surface; if a person
touches the contaminated object and touches their eyes, mouth, or nose they may become
inoculated with influenza (CDC, 2018). Most often, the disease is directly transmitted by
respiratory droplets when an infected individual coughs, sneezes, or talks (WHO, 2018).
The droplets land on the mouths and noses of nearby individuals and are inhaled into the
lungs (CDC, 2018). This type of transmission follows the epidemic pattern of propagated
transmission, utilizing humans as a host for infection (CDC, 2012). These outbreak types
have infection levels that peak during the incubation period, which is two days on
average, but can range from one to four days after a group has been exposed to influenza
(CDC, 2012; WHO, 2018). After incubation, during the prodromal period, one may have
mild to no symptoms and contribute to the transmission of the virus before one even
knows they are sick (CDC, 2018). Next, the highest viral titers occur within one to two
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days of infection and symptoms are apparent; once this point is reached, high levels of
virus are maintained for up to six days where most of the susceptible epithelial cells are
infected, then the virus begins to decline (Smith, 2018). During this time of infection,
bacterial and viral pathogens can cause secondary infections that increase disease severity
(Smith, 2018).
Influenza’s high disease severity is due to the body’s lack of immunity against
different strains of the influenza virus (WHO, 2018). These strains arise due to rapid
mutation of surface glycoproteins causing antigenic drift (Potter, 2001). Mutations of
these antigenic surface molecules allow humoral immune response evasion because the
antibodies responding to the original virus are no longer effective against the newer
variants (Abbas, 2020). Influenza surface glycoproteins include haemagglutinin and
neuraminidase which are normally targeted by antibodies when immunity has been
developed, and mutations render the influenza virus unrecognizable even if an individual
has been previously infected by a different, related variant (Potter, 2001). The highly
transmissible and pandemic causing Influenza A has different subtypes due to
haemagglutinin and neuraminidase mutations, including the currently circulating viruses
of H1N1 and H3N2 (WHO, 2018).
When the influenza A virus infects a host, it causes an acute infection of the upper
and lower respiratory tracts (Smith, 2018). The immune system attempts to prevent this
infection. Upon one’s first exposure, innate immunity provides the first line of defense
(Abbas, 2020). The virus must first invade physical barriers, such as the epithelium which
has tight junctions covered by mucous or keratin to mechanically prevent infection
(Abbas, 2020). The influenza virus penetrates mucus membranes by removing them, as
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neuraminidase glycoproteins cleave sialic acids that make up the mucus, which allows
contact with underlying cells (Zanin, 2016). The viral envelope then binds respiratory
cells when HA attaches to sialic acid on the host cell membrane (Moreira, 2021). Next,
the viral envelope fuses with the host membrane, releasing the nucleocapsid to the
cytoplasm where it is uncoated, replicated, translated, and released to infect healthy cells
(Moreira, 2021). After physical barriers have been bypassed, the virus enters the tissues
(Abbas, 2020). Receptors of the innate immune system recognize thousands of molecular
patterns including damage-associated molecular patterns (DAMPS) and pathogenassociated molecular patterns (PAMPS), such as the single-stranded RNA of influenza
(Abbas, 2020). After these patterns are recognized, the innate immune system protects
the body by causing inflammation and activation of dendritic cells, macrophages,
neutrophils, and plasma proteins to eliminate extracellular microbes, phagocytize and
destroy pathogens, cause damage and tissue necrosis, and initiate tissue repair (Abbas,
2020). Once the virus has infected a cell, the innate intracellular response attempts to
eliminate cells through the Natural Killer (NK) cell response (Abbas, 2020). NK cell
granule secretions cause infected cells to undergo apoptosis, macrophages that
phagocytize infected cells are activated by Interferon γ (IFN-γ), and type I Interferon
(IFN) cytokines induced by Rig-Like Receptor recognition of viral RNA block viral
replication (Abbas, 2020). Lastly, the innate immune system defends against viruses by
aiding the activation of the adaptive immune system, which targets specific antigens
(Abbas, 2020).
Upon subsequent exposures the immediate innate response does not respond
differently; however, the adaptive response is quicker and stronger. This is because
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during the first exposure the humoral and cell-mediated responses must be activated and
pathogen-specific cells must grow in numbers and mature to respond to the virus,
resulting in the adaptive response taking seven to ten days to develop (Abbas, 2020). The
primary cell-mediated response targets protein antigens via T cells. Recognition occurs
by two pathways for exogenous and endogenous antigens. Exogenous antigens are
internalized by antigen-presenting cells, such as B-cells and macrophages, that present
the antigen by the MHC Class II pathway where CD4+ T-cells are presented with
unfolded proteins and co-stimulatory molecules from antigen-presenting cells to become
activated (Abbas, 2020). After activation, these cells proliferate and function to activate
macrophages to eliminate the exogenous antigen (Abbas, 2020). Endogenous antigens are
found within cells and presented through the Class I MHC pathway for all nucleated cells
(Abbas, 2020). CD8+ T-cells, which are the primary response against viruses, then
recognize these endogenous antigens and cause the cell to undergo apoptosis through
degranulation (Abbas, 2020). During the primary humoral response, B cells must be
activated before they respond to antigens. B-cells can be T-independent or T-dependent
and each is activated differently and respond to different molecules. Most B-cells are Tdependent and respond to proteins, such as HA and NA on influenza (Abbas, 2020). Tdependent activation requires two signals for activation, including CD4+ T-cell stimulus
and antigen binding to the variable Fab portion of the B-cell receptor (Abbas, 2020). The
interaction of stimulatory molecules on the B-cell and T-cell leads to class switching and
affinity maturation. Class switching occurs as regions downstream from the variable
domain are spliced to obtain M, D, A, E, and G antibody classes (Abbas, 2020). These
antibody classes each play different roles in defending against viruses like influenza by
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eliminating antigens. IgM plays a major role in the activation of the classical complement
pathway, which leads to inflammation, opsonization, and cell lysis; IgG is important for
neutralization, opsonization, and antibody-dependent cellular cytotoxicity; and IgA
prevents infection as it is secreted in the mucus (Abbas, 2020). Affinity maturation
occurs as variable regions that bind antigen undergo rapid mutation. Regions with a
higher affinity to the pathogenic antigen are selected, resulting in a more efficient
response (Abbas, 2020). T-independent B-cells are also important response mechanisms
as they recognize polysaccharides, lipids, and nucleic acids (Abbas, 2020). Activation
occurs as B-cells encounter non-protein antigens that cross-link on the antibody receptor
surfaces, resulting in the rapid production of IgM (Abbas, 2020). After the second
exposure, the adaptive response retains memory B cells and memory T cells. These
memory cells allow for the rapid proliferation of T-cells and B-cells upon repeated
exposures to antigens, creating a quick response as early as two to seven days after
exposure (Abbas, 2020).
Vaccination and Immunologic Reactions
Natural exposure to influenza antigens causes natural active immunity consisting
of B-cell and T-cell responses against the virus. B-cell and T-cell immunity can also be
induced through artificial active vaccination, which induces a primary immune response
(Clem, 2011). This type of vaccination occurs when live-attenuated viruses are
administered by intranasal pathways or dead-inactivated viruses are injected
intramuscularly (Clem, 2011). These antigens stimulate the immune system as they are
internalized by antigen-presenting cells, allowing for the activation and differentiation of
B-cells and T-cells (Clem, 2011). These B-cells and T-cells become memory cells after
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the antigen is eliminated, creating a long-lasting response (Clem, 2011). Upon subsequent
exposure to natural antigens, the body will respond faster and stronger to eliminate the
antigen and decrease the negative effects of influenza (Clem, 2011).
Natural passive immunity also protects against the influenza virus. Natural
passive immunity is humoral antibodies acquired as the result of transfer from mother to
fetus (Clem, 2011). This concept is particularly important for the vulnerable population
of newborns because deaths are fifteen times higher during the first four weeks after birth
because the immune system is not developed so they are highly vulnerable to disease
(WHO, 2011). The transfer of IgA and IgG through the colostrum and milk after birth
provides short-term protection for these newborns until their immune system is mature
and they can be vaccinated (Clem, 2011). When newborns with maternal immunity are
challenged with the influenza virus, epithelial barriers with IgA in mucus membranes
prevent viral entry (Abbas, 2020). If the virus bypasses anatomical barriers, IgG within
the tissues and blood bind influenza epitopes to neutralize the virus and prevent cellular
entry so the virus cannot spread (Abbas, 2020). IgG also plays an important role in
eliminating the antigen as its functions include neutralization, opsonization, and
antibody-dependent cellular cytotoxicity (Abbas, 2020). IgG plays a role in opsonization
because it tags viral particles for phagocytosis, allowing phagocytes to ingest and destroy
the pathogen (Abbas, 2020). IgG also triggers antibody-dependent cellular cytotoxicity,
causing natural killer cells to degranulate and destroy cells with endogenous antigens
(Abbas, 2020). Both IgA and IgG play a major role in the prevention of infection, so
newborns with no antibody protection against influenza are much more susceptible to
infection and severe disease outcomes (Abbas, 2020). Since active vaccination is not
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recommended until six months of age, early immunity through passive antibody transfer
is essential to survival as the number of respiratory illnesses, fever, and hospitalization
rates in newborns are decreased for those with vaccinated mothers (Kalenik, 2014).
Mothers without protection against influenza are also more susceptible to
infection and severe disease outcomes. During pregnancy, mothers are
immunosuppressed to prevent the immune system from attacking foreign fetal cells
(Becker, 2012). As a result, T-regulatory cells inhibit reactions that attack foreign and
self-antigens (Becker, 2012). This protects the fetus from conditions like spontaneous
miscarriage or preeclampsia; however, it increases pregnant women’s vulnerability to
diseases, such as influenza (Becker, 2012). Flu-related complications, including
pneumonia, occur at higher instances for pregnant women than in the general population
(Becker, 2012). Since this population is at risk, the CDC states pregnant women should
be vaccinated against seasonal influenza (Becker, 2012). When the vaccinated population
encounters influenza antigen, even with immunosuppression, T-cells and B-cells will
proliferate to eliminate the antigen; whereas the unvaccinated population experiences a
slow primary response that is more likely to be halted by regulatory T-cells (Abbas,
2020). The immune response in those who have been vaccinated protects against primary
infection and decreases the possibility of secondary infection because they experience a
shorter period between infection and convalescence (Abbas, 2020). Maternal health is
important because poor health is linked with child mortality (WHO, 2011). Providing
care to mothers, including vaccination, during pregnancy increases child survival rates
(WHO, 2011). Vaccination prevents fever and illness, which can harm the fetus during
pregnancy (CDC, 2018). For example, women who experienced fever during pregnancy
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were two times more likely to have a baby with a neural tube defect compared to mothers
who did not have a fever (CDC, 2018). This evidence reinforces the importance of
vaccination to protect the mother and fetus.
History of Vaccines
Historically, vaccination has been important for controlling the transmission,
infection, and severe effects of influenza (Barberis, 2016). The first step to creating these
vaccines was the isolation of the influenza virus. This began during the 1918-19
pandemic when scientists believed that an agent different from bacteria was transmitting
the disease, and in 1933 the influenza A virus was first isolated from the nasal secretions
of human patients (Barberis, 2016). From 1933 to 1936 scientists worked on important
laboratory techniques, including in vitro viral transmission, viral growth, viral
inactivation, purification by centrifugation, and antibody generation and isolation
(Barberis, 2016). The first clinical trials of inactivated vaccines occurred during the midthirties (Barberis, 2016). The first of these trials occurred in 1937 with soldiers in
England being vaccinated subcutaneously with an inactivated virus isolated from a mouse
lung (Barberis, 2016). The second trial of an inactivated influenza vaccine, in 1938,
rendered the US military protected from influenza. In the 1940s, the first widespread
vaccine was a monovalent influenza A vaccine, which means it contained one subtype of
inactivated influenza A (Barberis, 2016). Clinical trials showed these vaccines were
effective, but they did not protect against a newly emerging influenza B, so a new
vaccine was needed (Barberis, 2016). In 1942, a bivalent vaccine with influenza A and B
was utilized (Barberis, 2016). Due to the mismatch seen between influenza A and B, the
World Health Organization (WHO) created a global surveillance system with several
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countries in 1952 (Barberis, 2016). The systems allowed vaccines to be made based on
the previous season’s viral influenza (Barberis, 2016). Due to the 1968 pandemic, split
trivalent vaccines were created as they produced fewer reactions than whole virus
vaccines, especially for children (Barberis, 2016). These vaccines were less immunogenic
and yielded less protection than whole virus vaccines, so highly immunogenic, tolerable
subunit vaccines containing isolated and purified HA and NA surface antigens were
created using genetic reassortment in 1976 (Barberis, 2016). Live attenuated vaccines
were also important for early vaccination with clinical trials occurring in 1935-1941, and
in 1949 cell cultures were used for attenuated viral growth (Barberis, 2016). This type of
vaccine was authorized in the United States in 2003 for intranasal use (Barberis, 2016).
Around 2009 adjuvants, such as alum and oil in water, were applied to increase the
antigenicity of vaccines to increase immune reactions (Barberis, 2016). Another new
technique, developed in 2011, is the intradermal delivery of vaccines to involve dermal
antigen-presenting cells for increased immunological response (Barberis, 2016). Next, the
quadrivalent vaccine, an inactivated, split vaccine composed of two influenza B and two
influenza A strains, was approved by the United States in 2012 to decrease mismatch and
maintain immunogenicity (Barberis, 2016). To increase immunogenicity, in 2013, the
FDA approved a recombinant trivalent vaccine with a threefold higher HA dose. Finally,
scientists are currently developing universal vaccines that target conserved M2e or
hemagglutinin stalk proteins and exploit T-cells to cause broader antibody responses
(Barberis, 2016).
Current vaccine types are live-attenuated, recombinant, and dead-inactivated
vaccines (WHO, 2018). The WHO currently recommends the quadrivalent vaccine due to
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its wider protection against the most representative influenza strains, including H1N1,
H3N2, BYamagata, and BVictoria (WHO, 2018; WHO 2020). Injectable forms of the
influenza vaccine include recombinant and dead-inactivated vaccines, and intranasal
forms include live-attenuated vaccines (WHO, 2018). Recombinant vaccines are
produced using recombinant DNA technology, so it does not require virus grown in eggs
(CDC, 2021). Inactivated vaccines are created using heat, cold, irradiation, or chemicals
to destroy a pathogen and create a stable vaccine that can be easily transported (Clem,
2011). Live-attenuated vaccines contain a weakened virus, such as cold-adapted live
attenuated influenza vaccines (Clem, 2011). Since these vaccines contain the live
pathogen, they elicit a stronger and longer-lasting immune response (Clem, 2011). Other
important vaccines to recognize are flu vaccination by jet injector approved for ages 1864, high-dose flu vaccine with four times the antigen for those 65 and older, and cellbased vaccines cultured from a mammalian origin (CDC, 2021).
Surveillance is essential for these vaccines to be effective. The quadrivalent
vaccine has two influenza A and two influenza B subtypes, but these must be circulating
in the population for the vaccines to be protective (WHO, 2018). Surveillance and
predictions are utilized as epidemics seen in the Eastern and Southern hemispheres form
the basis of the vaccine for Europe and North America (Potter, 2001). Sometimes these
predictions are inaccurate due to different subtypes affecting North America and Europe,
so the vaccine is less effective (Potter, 2001). As a result, the flu season experiences
increased transmission, mortalities, and morbidities (Potter, 2001). The number of
mortalities and morbidities also depends on the number of people who are vaccinated. In
the United States, the percentage of adults over eighteen receiving the vaccine was
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48.1%, while the number of children aged six months to seventeen years was 52.5% over
the past year (CDC, 2022). Due to higher vaccination rates, the United States has 1.8
deaths per 100,000 due to influenza compared to 2.29 per 100,000 in South Africa (CDC,
2022; Gul, 2018). This difference is because antigens within the vaccine stimulate a
primary response against the influenza virus, allowing a faster and stronger secondary
response when exposed naturally (Abbas, 2020). Stronger immune responses due to
vaccination reduce the risk of flu illness between 40-60%; those infected experience a
31% lower risk of death and 26% lower risk of severe illness (CDC, 2021). Overall,
vaccination prevents death and hospitalization, while decreasing the time with illness in
those infected with influenza.
The Pig Model
The pig model is used due to its similarities with humans as newborns lack
antibodies when they are born due to having a non-invasive placental barrier, so
antibodies must be transferred through a mother pig’s milk (Salmon, 2009). These
antibodies provide lactogenic immunity to local pathogens until vaccination is
recommended (Salmon, 2009). Antibodies are transferred through breastfeeding with IgG
and IgM transfer through the colostrum and IgA transfer through the milk (Salmon,
2009). Colostrum is a nutrient-rich fluid produced for several days after birth, while milk
is produced throughout breastfeeding (Uruakpa, 2002). IgG, IgM, and IgA are transferred
to the newborn through the gut as the antibodies undergo transcytosis into enterocytes to
provide immunity in the piglet (Salmon, 2009). Along with similarities to humans, the
species are relatively easy to care for, have large numbers of offspring, and are low-cost
(Salmon, 2009). Large litter sizes are important to decrease the effect of confounding
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variables and deviations on research outcomes (Langmeier, 2019). Low-cost specimens
and ease of care are important to ensure inexpensive, feasible research.
Clinical Relevance
The WHO and CDC recommend that pregnant women get vaccinated because it is
safe and effective (Becker, 2012; WHO, 2018). Clinical advocacy for the vaccine has
been increasing as clear scientific research supports the safety and efficacy of the flu
vaccine in pregnant women (CDC, 2021). The CDC analyzed reports of the Vaccine
Adverse Reporting System, finding no link between vaccination during pregnancy and
complications or adverse fetal outcomes (CDC, 2021). Large studies using CDC vaccine
safety data found no link between spontaneous abortion, miscarriage, adverse obstetric
events, premature delivery, and birth defects and vaccination (CDC, 2021). Evidence of
vaccine benefits include decreasing pregnant women’s chances of being hospitalized due
to influenza by 40%, decreasing the risk of fetal birth defects due to fever, and protecting
newborns from influenza post-birth (Lamppa, 2021). Since the vaccine is both safe and
effective, it should be implemented into prenatal care before each pregnancy as it is the
best way for pregnant mothers to protect themself and their babies from flu-related
complications (CDC, 2020). Without this vaccination, newborns are highly vulnerable to
influenza until they can receive the vaccination at the age of six months (Wild, 1999).
Purpose
Since no vaccination exists for infants under six months old, other methods such
as passive immunity must be explored (Wild, 1999). Studies have shown that maternal
influenza vaccination is associated with fewer respiratory illnesses during the first six
months of the life of a newborn (Vanderlubbe, 2017). We know that both IgA and IgG
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antibodies are important for protection against influenza virus infection (VanDerLubbe,
2017). However, we do not know whether decreased respiratory illness in infants is
related to the transfer of IgA in breastmilk or IgG from colostrum (Albrecht, 2020). To
help determine how infants can be protected, we tested the passive transfer of a universal
influenza vaccine using a pig model and researched the mechanism of transfer. This
model allowed us to determine whether the transfer of IgA from the mother’s milk and
IgG from the colostrum provided the antibody levels required for protection. Utilizing
research procedures, we tested the hypothesis that if vaccinated mother pigs transfer high
levels of antibodies to the newborn, then antibodies will protect influenza-challenged
offspring from the influenza virus.
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CHAPTER TWO
Materials and Methods
Procedure in Pigs
Testing whether antibodies are transferred was done by testing antibody levels
and the presence of the virus in nasal swabs using hemagglutination assays for influenza
challenged piglets. Using this procedure, we test whether transferred antibodies are
protecting pigs from infection. This protection requires a high level of antibodies, so we
determine whether these antibodies are passed down and if they are produced in a large
enough quantity to provide protection. Research began as four mother pigs (X6912,
X6913, X6914, and X6915) were vaccinated twice with the HA-129 broad immunity
influenza vaccine, and four mother pigs (X6721, X6910, X6704, and X6911) were
vaccinated once with PBS and once with the HA-129 vaccine prior to challenge with
viruses expressing the IA and IL influenza virus hemagglutinins. The pigs received their
first vaccine between 4/30 and 5/2 and their second vaccine between 5/15 and 5/17. The
mothers were farrowed between 6/23-6/25 and piglets were challenged with influenza
virus three days post-birth with the X6721, X6704, X6912, and X6914 groups challenged
with IA influenza virus hemagglutinins and X6910, X6911, X6913, and X6915 groups
challenged with IL influenza virus hemagglutinins. Nasal swabs were collected on day 0,
day 3, and day 5 post-inoculation.
MDCK Growth Media
MDCK growth media is essential to support the growth of Madin-Darby Canine
Kidney (MDCK) cell lines. The procedure to make MDCK growth media occurred under
a sterile hood using an aseptic technique, beginning by attaching a 500 mL sterile filter
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with a pump system to a one-liter bottle. Next, 100 mL of 10X Minimum Essential
Medium (MEM), 50 mL of Heat-inactivated Fetal Bovine Serum (FBS), 10 mL of
Antibiotic/ Antimycotic Solution, 10 mL of MEM Vitamin Solution, 10 mL of LGlutamine, 1 mL of Gentamicin, and about 320 mL of distilled water was added to the
filter; the pump was turned on for filtration. After this solution was filtered and the pump
was stopped, 30 mL of NaHCO3 and 470 mL of distilled water were added and filtered.
The complete solution appeared red and was checked for correct pH based on color.
MDCK growth media was stored in a 4℃ refrigerator for later use.
MDCK Infection Media
MDCK infection media is important to promote viral infection of MDCK cell
lines. The procedure to make MDCK infection media occurred under a sterile hood using
an aseptic technique, beginning by attaching a 500 mL sterile filter with a pump system
to a one-liter bottle. Next, 100mL of 10X MEM, 40mL of a 7.5% Bovine Serum Albumin
(BSA) in water, 10mL Antibiotic/Antimycotic solution, 10 mL MEM Vitamin Solution,
10 mL L-Glutamine, and 330 mL of distilled water was added to the filter; the pump was
turned on for filtration. After this solution was filtered and the pump was stopped, 30mL
NaHCO3 and 470 mL of distilled water were added and filtered. The complete solution
appeared red and was checked for correct pH based on color. MDCK infection media was
stored in a 4 ℃ fridge for later use.
Cell Culture and Plating Procedure
MDCK cells are used during experimentation due to their high susceptibility to
influenza infection (Seitz, 2010). Cell culture and plating procedures began with the
growth and maintenance of an MDCK cell line from stock media. These cells are seeded
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into a T-75 flask and incubated at 37℃ with 5% CO2. These cells were then passaged
when 90% confluency was reached and maintained in a larger T-150 flask. The passaging
procedure from one T-150 to another T-150 began as excess media was removed with a
pipet. Next, the cells were washed with 10 mL of PBS and excess PBS was removed. 1
mL of 0.5% trypsin and 9 mL of PBS were added to the flask, and it was incubated at
37℃ with 5% CO2 for one hour. Then, the cells were pipetted and placed into a corning
tube that was centrifuged at 2500 g for three minutes. The remaining PBS and trypsin
supernatant was removed, and the pellet was resuspended in 10 mL of MDCK Growth
Media. One milliliter of the media was allocated to another T-150 flask with 39 mL of
MDCK growth media and placed in the incubator at 37℃ with 5% CO2 to continue
MDCK cell growth for future experiments. 100 μL of resuspended cells from the
remaining 9mL solution was added to a small test tube with 400 μL of growth media and
500 μL of trypan blue. Ten μL of this solution was loaded into the hemocytometer and
cells were counted under the microscope. Growth media was added to dilute the
remaining solution to reach a concentration of 3 x 105. The solution was added to 48 well
plates with a concentration of 3 x 105 cells in 1 mL of solution for each well. The plates
were incubated at 37℃ with 5% CO2 overnight to achieve 85-90% confluency.
Infection Procedure (TCID 50)
To determine whether the influenza virus was present, a TCID50 test was
completed to reveal the concentration where 50% of the plated cells were infected. The
first step of the procedure was performing 10-fold serial dilutions to dilute viral stock
(nasal wash) using MDCK infection media. 900 μL of infection media was added to ten
test tubes as they are placed in an ice bath. Next, 1 mL of viral stock was added to tube 1
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and vortexed; it was serially diluted by taking 1 mL from the previously vortexed tube
and transferring it to the following tube with 900 μL of media followed by vortexing.
The incubated 48-well plates were removed and placed in the sterile hood. Media
was aspirated from each of the wells with a glass pipette. Each well was washed twice
with 250 μL of sterile 1X PBS and aspirated. 50 μL of the diluted virus was added to
each well with media added first, then adding the lowest (10-12) to the highest dilutions
(10-2). A1-A4 contained media, B1-B4 contained 10-2 concentration, C1-C4 contained 103

concentration, D1-D4 contained 10-4 concentration, E1-E4 contained 10-5 concentration,

F1-F4 contained 10-6 concentration, A4-A8 contained 10-7, B4-B8 contained 10-8
concentration, C4-C8 contained 10-9 concentration, D4-D8 contained 10-10 concentration,
E4-E8 contained 10-11 concentration, and F4-F8 contained 10-12 concentration. The plate
was incubated at 37℃ with 5% CO2 tapping every 15 minutes to ensure proper
distribution of the viral sample across the monolayer. The virus inoculum was aspirated
and 500 μL of MDCK infection media with 1 μg/mL TPCK Trypsin was added to the
wells. Plates were incubated at 37℃ with 5% CO2 for 72 to 96 hours. Cells were
observed for cytopathic effects due to the presence of the virus. Each treatment group
followed the same procedure.
Preparation of Chicken Red Blood Cells Procedure
Chicken red blood cells (CRBC) with Alsevers solution were resuspended before
transfer to conical tubes. 12 mL of CRBC was transferred to 15 mL tubes and centrifuged
at 1,338 g for four minutes at 25℃. Supernatant and the white blood cell layer were
removed to preserve the CRBC layer. 10 mL of 1X PBS was added to each tube with
CRBC and the solution was centrifuged at 800 g for 20 minutes at 25℃. 0.5 mL of
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CRBC from these tubes was added to 100 mL of 1X PBS and resuspended. The cells
were stored at 4℃ for later HA assay use.
Hemagglutination (HA) Assay
HA assays are used to determine the presence and concentration of the influenza
virus in a sample using titers. It utilizes properties of red blood cell binding as influenza
viruses bind to RBCs forming a lattice structure (CDC, 2021). This characteristic of
hemagglutination keeps RBCs suspended in solution when influenza virus is present as
opposed to sinking and forming a pellet when the virus is absent (CDC, 2021). Once 7296 hours of inoculation was complete, media for two samples were transferred to a
ninety-six well plate by pipetting up and down in each well before transferring to the
appropriate location. 50 μL of 0.5% CRBC solution was added to each well and the
solution remained undisturbed for thirty minutes before reading the results. The results
were analyzed for the absence (pellet) or presence (hemagglutination) of influenza virus
with a presence at the lowest concentration indicating titer values.
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CHAPTER THREE
Results
In challenged piglets, viral titers were obtained via HA assays to confirm and
quantify influenza virus presence along with TCID50s. These techniques allowed us to
test for the presence of virus in piglets of vaccinated and unvaccinated mothers. Mothers
vaccinated with PBS (Figures 1.1-1.8) produced piglets with higher viral titers than
influenza vaccinated mothers (Figures 2.1-2.8). Mean titers for Figures 1.1 and 1.2
(X6704) were 2468.5 for non-baseline values, 1662.3 for days 2-5, 903.59 for days 0-5,
50 for day 0, 50 for day 3, 50 for day 4, and 2123 for day 5. Mean titers for Figures 1.3
and 1.4 (X6721) were 50 for days 0-5, 50 for day 0, 50 for day 3, 50 for day 4, and 50 for
day 5. Mean titers for Figures 1.5 and 1.6 (X6910) were 133.35 for non-baseline values,
92.9 for days 2-5, 65.63 for days 0-5, 50 for day 0, 66.67 for day 2, and 133.35 for day 5.
Mean titers for Figures 1.7 and 1.8 (X6911) were 50 for days 0-5, 50 for day 0, and 50
for day 5. The overall mean titer value for PBS vaccinated mothers on days 2-5 was
691.8. Mean titers for Figures 2.1 and 2.2 (X6912) were 1000 for non-baseline values,
525 for days 2-5, days 0-5, 50 for day 0, and 525 for day 5. Mean titers for Figures 2.3
and 2.4 (X6913) were 567.5 for non-baseline values, 285.2 for days 2-5, 173.22 for days
0-5, 50 for day 0, 50 for day 3, and 308.769 for day 5. Mean titers for Figures 2.5 and 2.6
(X6914) were 50 for days 0-5, 50 for day 0, and 50 for day 5. Mean titers for Figures 2.7
and 2.8 (X6915) were 50 for days 0-5, 50 for day 0, 50 for day 3, and 50 for day 5. The
overall mean for HA-129 vaccinated mothers on days 2-5 was 258.1. These means reveal
lower titers and greater protection for mothers receiving HA vaccination.
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Figure 1.1: Graph of Titer Values for Piglets of PBS Vaccinated Mother X6704 Days 0-5
Figure 1.2: Table of Titer Values for Piglets of PBS Vaccinated Mother X6704 Days 0-5
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Figure 1.3: Graph of Titer Values for Piglets of PBS Vaccinated Mother X6721 Days 0-5
Figure 1.4: Table of Titer Values for Piglets of PBS Vaccinated Mother X6721 Days 0-5
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Figure 1.5: Graph of Titer Values for Piglets of PBS Vaccinated Mother X6910 Days 0-5
Figure 1.6: Table of Titer Values for Piglets of PBS Vaccinated Mother X6910 Days 0-5
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Figure 1.7: Graph of Titer Values for Piglets of PBS Vaccinated Mother X6911 Days 0-5
Figure 1.8: Table of Titer Values for Piglets of PBS Vaccinated Mother X6911 Days 0-5
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Figure 2.1: Graph of Titer Values for Piglets of HA-129 Vaccinated Mother X6912 Days 0-5
Figure 2.2: Table of Titer Values for Piglets of HA-129 Vaccinated Mother X6912 Days 0-5
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Figure 2.3: Graph of Titer Values for Piglets of HA-129 Vaccinated Mother X6913 Days 0-5
Figure 2.4: Table of Titer Values for Piglets of HA-129 Vaccinated Mother X6913 Days 0-5
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Figure 2.5: Graph of Titer Values for Piglets of HA-129 Vaccinated Mother X6914 Days 0-5
Figure 2.6: Table of Titer Values for Piglets of HA-129 Vaccinated Mother X6914 Days 0-5
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Figure 2.7: Graph of Titer Values for Piglets of HA-129 Vaccinated Mother X6915 Days 0-5
Figure 2.8: Table of Titer Values for Piglets of HA-129 Vaccinated Mother X6915 Days 0-5
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Figure 3: Graph of Mean Titers for Piglets of HA-129 vs PBS Vaccinated Mothers on Days 2-5
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Along with higher mean values, the data presented showed higher titer values in
those vaccinated with PBS vs HA-129. X6704 attained the highest two titer values at
4216.97 for those vaccinated with PBS, while the highest for those vaccinated with HA129 was 1000. It is interesting to note that piglets with the most positive results in the
PBS group (X6704) had high titer values indicating infection, except X6704-3 and
X6704-5 which had baseline values. Meanwhile, the piglets with the most positive results
in the HA-129 vaccinated group (X6913) had much lower titer values and increased
numbers of baseline values (X6913-3, X6913-4, X6913-6, X6913-9, X6913-10),
indicating levels of protection. The group with the second-highest infections for PBS vs
HA-129 also exhibited greater protection for the HA-129 vaccinated pigs. X6910-PBS
shows three infections within piglets with values reaching as high as 133.35 on only day
two, while X6912-HA129 exhibits only one breakthrough infection on day 5. Lastly, two
groups for PBS and HA-129 vaccination show no levels of infection due to the innate
(PBS vaccinated) or adaptive (HA-129) immune system preventing entry and infection.
An unpaired t-test was used to analyze the data and evaluate the two-tailed pvalues. The test gave a p-value of 0.2083, and since this value is greater than 0.05, we are
unable to accept our hypothesis that if vaccinated mother pigs transfer high levels of
antibodies to the newborn, then antibodies will protect influenza-challenged offspring
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from the virus. Although the number is not found to be statistically significant, we can
note that the p-value is not 0.5, so the data does point to the possibility that the vaccinated
group was better protected against influenza. This possibility is supported as the mean of
those vaccinated with PBS minus the mean of those vaccinated with HA-129 indicated a
value of 433.9019 on days 2-5, indicating much higher titer values for the PBS group
overall. The 95% confidence interval of this difference ranges from -252.35 to 1120.15,
revealing a much higher possibility the value is greater than one, indicating higher titer
values and less protection for the PBS group. Numbers used in these calculations were t =
1.28, df = 38, and standard error of difference = 338.992.
Sources of error prevent us from definitively confirming our hypothesis. First, the
data lacks large numbers of sampling on days 2-5 after inoculation due to sample
shipping issues during the COVID-19 pandemic, which resulted in unprocessed samples.
When these samples were processed in the Ying lab, the trend for higher viral titer values
in the PBS group continued with statistical significance. Next, data may be skewed due to
the high number of day 0 samples at a baseline of 50 that we used for training purposes.
Lastly, error within the vaccination procedure of pigs interferes with outcomes as the
study intended to have a true PBS group, but the first vaccination occurred with PBS and
the second with HA-129. The study has been repeated with a true PBS group and these
samples are currently being processed. Preliminary research in the Ying lab has found
significantly increased lung lesions and higher viral titers in the PBS group compared to
the HA-129 vaccinated group. Through this research, we can predict influenza
vaccination of mothers leads to the protection of piglets through the passive transmission
of IgA and IgG antibodies in the milk and colostrum.
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CHAPTER FOUR
Discussion
Data Summary and Comparison to Other Research
Our data revealed higher means for viral titer values in the PBS vaccinated group
compared to the HA-129 vaccinated group, indicating higher levels of infection in the
PBS group. Combined with a P-value of 0.1813 we support the possibility that the
vaccinated group was better protected. Several studies support this possibility in mice,
chickens, and humans. Findings within a study of mice supported the idea that pregnant
women are immunocompromised as immune responses in pregnant female mice were
lower than in non-pregnant female mice (Vanderlubbe, 2017). The study revealed
maternal antibody transfer with longevity increasing as the mother received more
vaccines, supporting our research for maternal antibody transfer (Vanderlubbe, 2017).
When pups were weaned at three weeks of age, antibody levels started to decline,
supporting the idea that important IgA and IgG antibodies that protect against influenza
are transferred through the milk and colostrum (Vanderlubbe, 2017). This concept is
confirmed as research finds the status of vaccination of the mouse the offspring suckles
on is much more important than the vaccination status of the mother (Kalenik, 2014).
Further, the research conducted by Vanderlubbe et al. (2017) found maternal passive
immunity against the influenza virus does not interfere with future active vaccinations.
Overall, research with mice supports our prediction that influenza vaccination of mothers
leads to the protection of piglets through the passive transmission of IgA and IgG
antibodies in the milk and colostrum. Chickens do not feed their young via milk or
colostrum. A study of maternal immunity in chickens found with H5N1 inoculation,
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those with vaccinated mothers lived only a few days longer than control chicks with only
three out of thirty-two surviving, so vaccination of mothers did not significantly affect
survival time (Maas, 2011). Further, of the chickens with maternal immunity at birth,
antibody titers and protection quickly diminished, revealing lower results for protection
than in our pig and the mouse study (Maas, 2011). This study reveals the importance of
IgA and IgG transfer through milk and colostrum for the continued, effective protection
against the influenza virus. Clinical studies on humans also advocate for the dual
protective effects of influenza vaccination for the mother and fetus/newborn. A pooled
analysis of inactivated influenza vaccine in pregnant human mothers found 50% efficacy
in mothers and 35% efficacy in newborns for protection against laboratory-confirmed
influenza (Azziz, 2021). Each of the studies in mice, chickens, and humans support the
transfer of important IgA and IgG antibodies in colostrum and milk, reinforcing our
prediction of IgA and IgG transfer from mothers to protect piglets challenged with the
influenza virus.
Universal Vaccination and Humans
While the maternal transfer of antibodies may protect infants from severe
infection during the next pandemic, universal influenza vaccination may prevent the
recurrence of future pandemics and epidemics. Currently, there is a threat of G1 and G4
influenza virus emergence with the potential to cause a pandemic or an epidemic. Swine
surveillance indicates these subtypes contain triple reassortment derived internal genes,
the ability to bind human-type receptors, the ability to produce increased progeny in
human epithelial cells, and high aerosol transmission rates which aid the ability of the
virus to jump to humans; however, the G1 virus exhibited decreased ability to produce
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progeny in epithelial cells compared to the G4 virus (Sun, 2020). In infected ferrets, the
G1 virus caused mild clinical signs, whereas the G4 virus caused severe clinical
symptoms (Sun, 2020). The potential of high transmission rates and severe infection
abilities creates the concern of a future G4 H1N1 pandemic (Sun, 2020). Another cause
of concern is the current influenza vaccine does not provide antigen cross-reactivity with
the G1 and G4 influenza viruses (Sun, 2020). In a study of 20 serum samples from 4year-old children vaccinated with a trivalent vaccine, no serum samples reacted with the
G1 or G4 H1N1 viral strains (Sun, 2020). In addition, serological surveillance of swine
workers indicated 10.4% were infected with the G4 H1N1 virus and 6.5% were infected
with the G1 H1N1 virus, indicating the presence of the virus in the human population
(Sun, 2020). This increased infectivity is concerning as the population is not immune to
these viruses, increasing their ability to replicate within the host and adapt to increase
virulence (Sun, 2020). Utilizing the traditional vaccine would require reformulation with
G1 and G4 antigens to protect against infection (NIH, 2021). Vaccination with a
universal vaccine, such as the HA-129 influenza vaccine, can prevent a pandemic (such
as the G1 and G4 H1N1 threat) by providing broad protection against these strains. Our
broad-immunity HA-129 universal influenza virus was tested in pigs, but the National
Institutes of Health is launching its first human trial of a universal nanoparticle influenza
vaccine to provide long-lasting protection against multiple flu virus strains (NIH, 2021).
Within animals, this vaccine prompted a robust antibody response (greater than the
commercial vaccine) to HA components in monkeys, mice, and ferrets (NIH, 2021).
Furthermore, it outperformed the traditional vaccine in producing protective antibodies
against subtypes not found in the vaccine (NIH, 2021). Other universal vaccines target
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conserved viral stocks instead of the globular HA head that undergoes antigenic variation
(Corona, 2020). Stalk targeting creates the potential to protect against novel pandemic
influenza strains, preventing the emergence of viruses, including G1 and G4 H1N1 in the
human population. In addition to preventing the emergence of the virus, the universal
vaccine would decrease influenza escape which often leads to greater pathogenicity
(Estrada, 2019). The decrease in vaccine escape is due to targeting genetically conserved
components of influenza to create a long-lasting, robust, and widespread antibody and Tcell response (Estrada, 2019).
The universal vaccine increases pandemic preparation by having a viable vaccine
in clinical trials that could respond to wide ranges of influenza virus subtypes capable of
causing a pandemic. In contrast, vaccines capable of responding to COVID antigens in
humans had little development before the pandemic. The WHO ensured preparation to
distribute a vaccine, but the lack of vaccine development eliminated the possibility of
early clinical trials and early distribution (WHO, 2020). As a result, the WHO had to
respond by ensuring case management and prevention in hospitals (WHO, 2020). A lack
of viable vaccines created an urgency for development (Kiszewski, 2021). Funding for
innovative vaccine development is essential to respond to these emerging public health
threats; however, NIH funding for pandemic threats is inconsistent (Kiszewski, 2021).
Most of the $17.2 billion funding for vaccine technologies was allocated to current
threats, neglecting the threat of emerging diseases, such as COVID (Kiszewski, 2021).
From 2000-2019, select vaccine technologies that contributed to COVID vaccine
candidates included $9.65 billion for synthetic vaccines, $5.64 billion for adjuvants,
$4.58 billion for DNA vaccines, $4.05 billion for live-attenuated vaccines, $1.56 billion
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for viral vector-based vaccines, $1.47 billion for inactivated-virus vaccines, $1.06 billion
for TLR9 agonists, $943 million for mRNA vaccines, $583 million for virus-like
particles, and $519 million for nanoparticle-based vaccines (Kiszewski, 2021). This
funding focused on current threats as $9.18 billion was funded for HIV, $639 million for
Ebola, $767 million for coronavirus, $555 million for Zika, and $331 million for Dengue
(Kiszewski, 2021). These results reveal little funding was spent on coronavirus and
mRNA research; however, this research beginning before 2017 was essential to quickly
develop a COVID-19 vaccine candidate (Hogan, 2021). As a result of a lack of funding
and research preparedness, the world experienced a lack of vaccine development
readiness when the pandemic emerged (Kiszewski, 2021). This led to the implementation
of social distancing as the best way to avoid viral spread (Kiszewski, 2021).
Social distancing and high rates of infection negatively impacted the economy.
Income was reduced, transportation services ceased, and service and manufacturing
industries were halted (Front., 2020). The global economic downfall was caused by “loss
of life, business closures, trade disruption, and decimation of the tourism industry (Front.,
2020).” For example, in China, the production index decreased by 54% during the first
February of the pandemic (Front., 2020). By April 2020, the United States experienced a
record high unemployment rate of 11% (Front., 2020). In addition, global oil markets and
US stock markets declined (Front., 2020). Healthcare finances were also negatively
impacted as America’s hospitals and healthcare systems lost $50.7 billion per month
(Kaye, 2021). The world bank shrunk by 8% and the pandemic cost the global economy
two trillion dollars in one year (Kaye, 2021). These examples exhibit the negative
economic impacts of the pandemic caused by little economic preparation.

37

The world is much more prepared to overcome an influenza pandemic. The
universal vaccine presents excellent vaccine development readiness as a vaccine
candidate for broad influenza pandemics has already been created and placed in clinical
trials (NIH, 2021). These vaccines can be implemented for quick vaccine production and
broad population immunity. As a result, the wide response to influenza could prevent or
drastically decrease the impacts of a pandemic while protecting against seasonal
influenza drift variants (Paules, 2018). Having a readily available vaccine should
decrease severe illness and infections by decreasing stress on healthcare infrastructure.
Further, the constant financial cost of seasonal surveillance and vaccine production would
be decreased due to the broad, long-lasting immunity against subtypes of influenza.
Lastly, there would be little economic effect as lower morbidities due to protection would
decrease the loss of work hours due to infection.
A universal influenza vaccine also increases herd immunity to seasonal variants
(Paules, 2018). The long-lasting response eliminates the need to be vaccinated yearly for
protection, which may cause some patients to avoid vaccination (Lazar, 2018). For
example, low-income groups lack access to healthcare due to an inability to pay for care
or take time off work for an appointment, so having a one-time vaccine increases their
ability to get vaccinated and protected for long amounts of time (Lazar, 2018). As a
result, a universal vaccination would lead to an increased global vaccination rate,
increasing herd immunity. Herd immunity increases the protection of the general
population and vulnerable groups due to the decrease in host-to-host transmission (WHO,
2020). In addition, the vaccination elicits a strong B-cell and T-cell response, much like
the live-attenuated vaccine, but it does not pose a threat to immunocompromised
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individuals as the virus cannot be shed with this type of vaccine (Estrada, 2019). Immune
protection provided by the universal vaccine addresses the issues caused by influenza,
including decreased morbidity and mortality from severe illness (Sah, 2019). Further,
those vaccinated and protected from influenza will exhibit decreased symptom severity
when infected (Sah, 2019). A decrease in infection and symptom severity is predicted to
have a huge positive impact on decreasing healthcare infrastructure influenza burden
(Sah, 2019). Replacement of seasonal vaccines is projected to “reduce the influenza
burden by 11.5 million cases, 168,703 hospitalizations, 13,161 deaths, and $2.37 billion
in direct medical costs (Sah, 2019).” Along with decreasing the burden of direct medical
costs, the universal vaccine would decrease the general economic burden of influenza
epidemics and pandemics. Productivity losses due to infection would drastically decrease
because of the predicted high herd immunity (Sah, 2019). Overall, the universal vaccine
addresses the issues of pandemic prevention and preparedness, increasing immunity
against the influenza virus, and morbidities and mortalities caused by influenza.
Influenza and Pregnancy
Our research presents a case to advocate for the implementation of influenza
vaccination into prenatal care. Our data and literary research support the prediction that
milk and colostrum contain important IgA and IgG antibodies for the prevention of
infection and severe disease due to influenza. There is also clear literary evidence for the
protection of newborns with maternal influenza vaccination. It is the best way to prevent
adverse effects of influenza in both pregnant women and newborns up to six months old
(Rasmussen, 2019). In newborns, adverse effects of influenza are indirectly prevented as
preventing maternal infection reduces preterm birth, low birth weight, spontaneous
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abortion, and birth defects (Azziz, 2021). For example, a study of 27,000 women found
those who experienced fever due to influenza had greater instances of congenital
abnormalities (Azziz, 2021). Directly, newborns are protected by the transfer of maternal
antibodies until they can receive influenza vaccination at 6 months of life (Azziz, 2021).
The immunosuppressed mother is also protected as the risk of hospitalization due to
influenza is significantly higher for pregnant vs nonpregnant women (Azziz, 2021).
Maternal vaccination is not associated with adverse prenatal/ neonatal outcomes, so the
vaccine is safe and effective (Azziz, 2021). Data supports vaccination of mothers at any
gestational age due to plentiful data supporting the safety and benefits; however,
vaccination rates have decreased to about 50% (Azziz, 2021; Rasmussen, 2019).
Obstetric practitioners must increase their efforts and strategies to improve vaccination
rates to better protect newborns and mothers from adverse influenza outcomes
(Rasmussen, 2019).
Universal Vaccination and the Pork Industry
A potential influenza pandemic can have devastating effects on the pork industry.
The pandemic has direct negative effects as pigs are infected with the swine flu, causing
financial loss due to reduced growth rates and acute respiratory disease (Pig, 2021).
Along with the loss of livestock, the swine flu disrupts markets. For example, a few
weeks after the first 2009 H1N1 outbreak, domestic pork demand decreased and 27
countries blocked United States imports causing the US pork industry to lose $1.1 billion
in only six months (Pig, 2021).
The swine flu was transmitted through human-human or pig-human contact, and
15-25% of swine farmers had been exposed to the virus at work (Congressional, 2010).
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Even though humans could not get the infection through properly handled pork products,
negative perception and fear of swine caused financial loss. Domestic customers were
leery about buying pork, with 13% of people believing they could contract the disease by
eating pork (Congressional, 2010). This perception can be decreased by preventing
interspecies transmission.
Universal vaccination for humans against a wide range of influenza strains
prevents interspecies transmission. Prevention of interspecies and intraspecies
transmission by universal vaccination would have an enormous impact on the pork
industry in the face of a pandemic. Lower infection rates would decrease the negative
perception of pork, preventing a decrease in pork product purchasing that occurred during
the H1N1 pandemic. In addition, vaccinated pigs would be better protected, and
producers would save money based on decreased morbidity and mortality of livestock.
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CHAPTER FIVE
Conclusion
Results from the pig vaccine study indicate higher mean piglet titer values for
PBS vaccinated vs HA-129 vaccinated mother pigs indicating increased protection in the
HA-129 vaccination groups. Analysis reveals a p-value favorable of the hypothesis that if
vaccinated mother pigs transfer high levels of antibodies to the newborn, then antibodies
will protect influenza-challenged offspring from the virus. From the research, we can
predict that IgA and IgG antibodies transferred to piglets for the HA-129 vaccinated
group protected them from infection. Previous research of mice, chickens, and humans
supports the maternal transfer of IgA and IgG, which are important for defense against
influenza, through milk and colostrum. Further, research indicates passive protection of
newborns with a 35% efficacy against the virus, supporting our hypothesis that piglets
will be protected from adverse effects of influenza infection through passive maternal
immunity (Azziz, 2021). With support from our results, our study aimed to increase
advocacy for the vaccine with clear scientific research proving transferred protection to
the newborn. Understanding whether using a universal vaccine delivered to mother pigs
can transfer immunity to newborns is a step toward understanding whether a universal
vaccine could create greater herd immunity against the influenza virus in humans,
preventing deaths from the virus. The increased herd immunity would decrease influenza
rates and aid the protection of vulnerable populations, such as those with
immunodeficiency or the elderly. Furthermore, by studying whether this protects the
vulnerable population of newborns, a basis for advocating the timing of influenza
vaccination for pregnant women can be formed. Finally, because this vaccine is
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universal, it would not need to be changed from year-to-year, so it could be implemented
into the recommended prenatal care for pregnant women. Protection a universal influenza
virus vaccine would provide to the general and vulnerable populations would decrease
the annual large numbers of deaths and hospitalizations, the stress imposed on the
healthcare system, and the negative economic impacts due to influenza.
Before the possibility of a universal vaccine, research focused on seasonal
surveillance and vaccination against relevant influenza subtypes based on glycoproteins
with high mutation rates (WHO, 2018). These HA (receptor binding) and NA (receptor
destroying) glycoproteins allow pathogen attachment and release of virions (Hwang,
2020). After vaccination, antibodies and T-cells target these glycoprotein domains to
prevent viral entry and release, reducing the spread of infection (Hwang, 2020). By
preventing influenza infection through priming the immune response both seasonal and
universal vaccines protect against secondary bacterial infection (Smith, 2018). This
research shows that accurate protection against the influenza virus can be achieved by
targeting conserved components of epitopes within universal vaccines. Our universal
vaccine targets these conserved epitopes, such as the M2e protein which is present in all
subtypes of influenza viruses, to prevent entry and infection of influenza (Hwang, 2020).
These strategies have revealed protection against a broad spectrum of influenza subtypes
decreasing the need for seasonal surveillance and annual vaccination if implemented. The
aspect of broad-spectrum immunity and universal vaccines may be developed and
improved for future broad immunity against influenza subtypes (Hwang, 2020).
This research can be expanded upon in the future. First, future research can be
applied to definitively confirm the hypothesis that if vaccinated mother pigs transfer high
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levels of antibodies to the newborn, then antibodies will protect influenza-challenged
offspring from the virus. Additional research can be completed to determine the best
timing for maternal vaccination against influenza to promote the optimal immune
response in newborns. This research can be used to advocate for increased maternal
vaccination in the clinical setting by setting a definitive timeline for recommended
vaccination. Next, once a universal vaccine is approved for clinical use, research on herd
immunity and the protection of vulnerable populations can be studied. This will provide a
better source for protecting the elderly, infants, underprivileged groups, and
immunocompromised individuals. Along with research into protection against influenza,
the universal vaccine is being researched as a solution to COVID-19 to create a single
vaccine targeting both respiratory diseases (Hwang, 2020). This bivalent vaccine would
contain conserved SARS-CoV-2 and influenza antigens to provide a broad-spectrum
immunity against subtypes of both groups, decreasing the viability of antigenic mutation
as an effective way to evade the immune response (Hwang, 2020). Our research presents
an important step to confirming the viability of the universal influenza vaccine and
confirming the potential to expand universal vaccine research to emerging diseases in the
future.
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